South Korea
· Delayed Price · Currency is KRW Pharos iBio Statistics
Total Valuation
Pharos iBio has a market cap or net worth of KRW 96.21 billion. The enterprise value is 79.15 billion.
| Market Cap | 96.21B |
| Enterprise Value | 79.15B |
Important Dates
The next estimated earnings date is Friday, March 21, 2025.
| Earnings Date | Mar 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharos iBio has 12.93 million shares outstanding. The number of shares has increased by 10.01% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 12.93M |
| Shares Change (YoY) | +10.01% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 33.49% |
| Owned by Institutions (%) | 17.69% |
| Float | 8.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 4.72 |
| P/TBV Ratio | 4.75 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.39 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -8.73 |
Financial Position
The company has a current ratio of 29.32, with a Debt / Equity ratio of 0.01.
| Current Ratio | 29.32 |
| Quick Ratio | 28.60 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.02 |
| Interest Coverage | -1,641.40 |
Financial Efficiency
Return on equity (ROE) is -42.03% and return on invested capital (ROIC) is -29.47%.
| Return on Equity (ROE) | -42.03% |
| Return on Assets (ROA) | -28.70% |
| Return on Capital (ROIC) | -29.47% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -42.94% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -42.94% |
| 50-Day Moving Average | 8,749.00 |
| 200-Day Moving Average | 11,796.50 |
| Relative Strength Index (RSI) | 38.20 |
| Average Volume (20 Days) | 60,140 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -25.08M |
| Operating Income | -12.14B |
| Pretax Income | -10.71B |
| Net Income | -10.71B |
| EBITDA | -11.36B |
| EBIT | -12.14B |
| Earnings Per Share (EPS) | -829.26 |
Balance Sheet
The company has 17.22 billion in cash and 162.55 million in debt, giving a net cash position of 17.06 billion or 1,318.99 per share.
| Cash & Cash Equivalents | 17.22B |
| Total Debt | 162.55M |
| Net Cash | 17.06B |
| Net Cash Per Share | 1,318.99 |
| Equity (Book Value) | 20.36B |
| Book Value Per Share | 1,576.00 |
| Working Capital | 17.21B |
Cash Flow
In the last 12 months, operating cash flow was -8.59 billion and capital expenditures -480.79 million, giving a free cash flow of -9.07 billion.
| Operating Cash Flow | -8.59B |
| Capital Expenditures | -480.79M |
| Free Cash Flow | -9.07B |
| FCF Per Share | -701.29 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Pharos iBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.01% |
| Shareholder Yield | -10.01% |
| Earnings Yield | -11.15% |
| FCF Yield | -9.43% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |